Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CAD | P27708 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9082110 | 1.00 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10ALOX15CYP2D6 | |
| SCHEMBL1340978 | 0.98 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10ALOX15CYP2D6 | |
| Ethylene SCHEMBL11065335 | 0.93 | ALDH1A1 (0.44) | ALDH1A1LMNAHSD17B10ALOX15CYP2D6 | |
| Hydrochloric Acid SCHEMBL275716 | 0.87 | ALOX15 (0.50) | ALDH1A1LMNAHSD17B10ALOX15CYP2D6 | |
| SCHEMBL338079 | 0.85 | ALOX15 (0.52) | ALDH1A1LMNAHSD17B10ALOX15CYP2D6 | |
| Acetic Acid SCHEMBL28002636 | 0.83 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10ALOX15CYP2D6 | |
| Hydrochloric Acid SCHEMBL1437174 | 0.81 | ALOX15 (0.44) | ALDH1A1LMNAHSD17B10ALOX15CYP2D6 | |
| Hydrochloric Acid SCHEMBL3023531 | 0.79 | ALOX15 (0.42) | ALDH1A1LMNAHSD17B10ALOX15CYP2D6 | |
| Hydrochloric Acid SCHEMBL3023532 | 0.79 | ALOX15 (0.42) | ALDH1A1LMNAHSD17B10ALOX15CYP2D6 | |
| SCHEMBL28219320 | 0.79 | ALDH1A1 (0.38) | ALDH1A1LMNAHSD17B10ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768260-B1 | OXADIAZOLE COMPOUNDS AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-06-05 | — | — | US | disclosed |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2025-04-29 | — | — | US | disclosed |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12202824-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-4486743-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-01-08 | — | — | EP | disclosed |
| EP-3792256-B1 | PYRIDINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118765280-A | RIP1 modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-10-11 | — | — | CN | disclosed |
| EP-3704111-B1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2024-10-09 | — | — | EP | disclosed |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | disclosed |
| CN-1052672-A | Benzofuran derivative | GLAXO GROUP LTD (GB) | 1991-07-03 | — | — | CN | disclosed |
| EP-0434249-A2 | Benzofuran derivatives | GLAXO GROUP LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
| WO-1991007107-A1 | OXAZOLIDINEDIONE HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1991-05-30 | — | — | WO | disclosed |
| EP-0428312-A2 | Oxazolidinedione hypoglycemic agents | PFIZER INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| US-4879295-A | ANTIALLERGENS | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| EP-0262873-A1 | N-tetrazolyl thiazolecarboxamide derivatives and their use | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 1988-04-06 | — | — | EP | disclosed |
| EP-0096890-B1 | OXAZOLEACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING SAID DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 1987-11-25 | — | — | EP | disclosed |
| US-4602027-A | HYPOGLYCEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-07-22 | — | — | US | disclosed |
| US-4593118-A | 2-amido-3-aminocarboxylic acid esters and process of preparation thereof | ETHYL CORPORATION (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0096890-A2 | Oxazoleacetic acid derivatives, process for their production and compositions containing said derivatives | Takeda Chemical Industries, Ltd. (JP) | 1983-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202824-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | GAA 4340/4885ALDH1A1 721/4885LMNA 3183/4885 |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK3 | GAA 2211/4885ALDH1A1 4611/4885LMNA 2266/4885 |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | GAA 4340/4885ALDH1A1 721/4885LMNA 3183/4885 |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, IDH1 | GAA 2277/4885ALDH1A1 2036/4885LMNA 1657/4885 |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | GAA 657/4885ALDH1A1 2997/4885LMNA 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.